The development of a PET radioligand for imaging 5-hydroxytryptamine (5-HT) 6 receptors in the brain would, for the first time, enable in vivo imaging of this target along with assessment of its involvement in disease pathophysiology. In addition, such a tool would assist in the development of novel drugs targeting the 5-HT6 receptor. Methods: On the basis of in vitro data, GSK215083 was identified as a promising 5-HT6 radioligand candidate and was radiolabeled with 11 C via methylation. The in vivo properties of 11 C-GSK215083 were evaluated first in pigs (to investigate brain penetration and specific binding), second in nonhuman primates (to confirm brain penetration, specific binding, selectivity, and kinetics), and third in human subjects (to confirm brain penetration and biodistribution). Results: 11 C-GSK215083 readily entered the brain in all 3 species, leading to a heterogeneous distribution (striatum . cortex . cerebellum) consistent with reported 5-HT6 receptor densities and distribution determined by tissue-section autoradiography in preclinical species and humans. In vivo saturation studies using escalating doses of GSK215083 in primates demonstrated saturable, dose-dependent binding to the 5-HT6 receptor in the striatum. Importantly, 11 C-GSK215083 also exhibited affinity for the 5-HT2A receptor; however, given the differential localization of these 2 receptors in the central nervous system, the discrete 5-HT6 binding properties of this radioligand were able to be determined. Conclusion: These data demonstrate the utility of 11 C-GSK215083 as a promising PET radioligand for probing the 5-HT6 receptor in vivo in both preclinical and clinical species. The development of selective PET radioligands has facilitated the in vivo imaging of a range of targets in the central nervous system. Of these, the serotonergic system has received much attention with the development of PET radioligands for the 5-hydroxytryptamine (5-HT) 1A (1), 5-HT1B (2), 5-HT2A (3), and 5-HT4 receptors (4), along with the 5-HT transporter (5). However, efforts to produce useful radiotracers for other serotonergic proteins, in particular the 5-HT6 receptor, have had limited success (6).The 5-HT6 receptor is 1 of 14 distinct mammalian serotonin receptors expressed in the central nervous system, through which serotonin is involved in the regulation of several biologic processes (7). The role of the 5-HT6 receptor in the human brain is not yet clearly understood. However, its localization in the basal ganglia and limbic regions and the high affinity of several atypical antipsychotics suggest that this receptor subtype may participate in the serotonergic control of motor function, mood-dependent behavior, depression, and cognition. Preclinical studies have demonstrated that 5-HT6 receptor antagonism can exert cognitive enhancing effects, in part by inducing increases in the extracellular levels of neurotransmitters in the frontal cortex (8). These properties suggest a potential utility for 5-HT6 receptor antagonists in the treatment of co...